Cargando…
Towards an anti-fibrotic therapy for scleroderma: targeting myofibroblast differentiation and recruitment
BACKGROUND: In response to normal tissue injury, fibroblasts migrate into the wound where they synthesize and remodel new extracellular matrix. The fibroblast responsible for this process is called the myofibroblast, which expresses the highly contractile protein α-smooth muscle actin (α-SMA). In no...
Autor principal: | Leask, Andrew |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2890590/ https://www.ncbi.nlm.nih.gov/pubmed/20507556 http://dx.doi.org/10.1186/1755-1536-3-8 |
Ejemplares similares
-
Thrombin-induced CCN2 expression as a target for anti-fibrotic therapy in scleroderma
por: Leask, Andrew
Publicado: (2009) -
Getting Out of a Sticky Situation: Targeting the Myofibroblast in Scleroderma
por: Leask, Andrew
Publicado: (2012) -
Therapeutic Targeting of Redox Signaling in Myofibroblast Differentiation and Age-Related Fibrotic Disease
por: Sampson, Natalie, et al.
Publicado: (2012) -
Scar wars: is TGFβ the phantom menace in scleroderma?
por: Leask, Andrew
Publicado: (2006) -
The Anti-Fibrotic Effect of Cold Atmospheric Plasma on Localized Scleroderma In Vitro and In Vivo
por: Arndt, Stephanie, et al.
Publicado: (2021)